BOSTON --"Emerging" therapeutic companies focused on developing treatments for depression and pain have starved for financing over the past decade while cancer drug developers have feasted on the largest share of investment capital, according to a trio of reports discussed here at the 2018 Biotechnology Innovation Organization (BIO) International Convention. Last year alone, 113 emerging companies--which have a lead candidate in clinical phases, or on the market with less than $1 billion in sales--focusing on oncology captured $2.918 billion in venture capital (VC) funding, more than one-third (37%) of the total $7.793 billion raised by 330 companies, according to Emerging Therapeutics Company Investment and Deal Trends . A mere $14 million in VC money was raised in 2017 by a single unidentified company, while pain therapy developers did a little better as nine companies raised a combined $171 million, the report stated. Between 2008 and 2017, $13.138 billion in VC was invested in cancer treatment companies, compared with $1.398 billion in pain ...